Identifying the Conditions Under Which Antibodies Protect Against Infection by Equine Infectious Anemia Virus.
Bottom Line:
A more complete understanding is needed of antibody protection against lentivirus infection, as well as the role of mutation in resistance to an antibody vaccine.In addition, a three-strain competition model is considered in which a second mutant strain may coexist with the first mutant strain.The conditions that permit viral escape by the mutant strains are determined, as are the effects of variation in the model parameters.
View Article:
PubMed Central - PubMed
Affiliation: School of Biological Sciences and Department of Mathematics, Washington State University, Pullman, WA 99164, USA. ejs@wsu.edu.
ABSTRACT
The ability to predict the conditions under which antibodies protect against viral infection would transform our approach to vaccine development. A more complete understanding is needed of antibody protection against lentivirus infection, as well as the role of mutation in resistance to an antibody vaccine. Recently, an example of antibody-mediated vaccine protection has been shown via passive transfer of neutralizing antibodies before equine infectious anemia virus (EIAV) infection of horses with severe combined immunodeficiency (SCID). Viral dynamic modeling of antibody protection from EIAV infection in SCID horses may lead to insights into the mechanisms of control of infection by antibody vaccination. In this work, such a model is constructed in conjunction with data from EIAV infection of SCID horses to gain insights into multiple strain competition in the presence of antibody control. Conditions are determined under which wild-type infection is eradicated with the antibody vaccine. In addition, a three-strain competition model is considered in which a second mutant strain may coexist with the first mutant strain. The conditions that permit viral escape by the mutant strains are determined, as are the effects of variation in the model parameters. This work extends the current understanding of competition and antibody control in lentiviral infection, which may provide insights into the development of vaccines that stimulate the immune system to control infection effectively. No MeSH data available. Related in: MedlinePlus |
![]() Related In:
Results -
Collection
License getmorefigures.php?uid=PMC4494265&req=5
vaccines-02-00397-f005: The long-term outcome using the sample values in Table 1 for the case when both mutants have 100-fold resistance (pM1 = 0.01pW, pM2 = 0.01pW) as the antibody magnification factor m varies. (A) m = 1; (B) m = 10; (C) m = 50; (D) the same as (C), except with no initial mutants. Mentions: The outcomes from changing antibody infusion and relative effectiveness. |
View Article: PubMed Central - PubMed
Affiliation: School of Biological Sciences and Department of Mathematics, Washington State University, Pullman, WA 99164, USA. ejs@wsu.edu.
No MeSH data available.